New hope for tough childhood cancer: experimental combo targets High-Risk tumors
NCT ID NCT07355855
Summary
This study is testing whether adding a vitamin A-based drug (all-trans retinoic acid) to standard chemotherapy (VAC regimen) works better against intermediate-to-high-risk rhabdomyosarcoma, a rare but aggressive muscle cancer. It will involve 106 patients aged 14-60 who haven't had any prior cancer drug treatment. Researchers will measure if this combination helps patients live longer without their cancer returning and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university cancer hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.